Free Trial
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Rigel Pharmaceuticals logo
$39.31 -0.42 (-1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$39.30 -0.01 (-0.03%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Key Stats

Today's Range
$39.05
$41.00
50-Day Range
$18.42
$41.99
52-Week Range
$12.66
$43.72
Volume
828,117 shs
Average Volume
311,775 shs
Market Capitalization
$705.22 million
P/E Ratio
7.27
Dividend Yield
N/A
Price Target
$38.20
Consensus Rating
Hold

Company Overview

Rigel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

RIGL MarketRank™: 

Rigel Pharmaceuticals scored higher than 32% of companies evaluated by MarketBeat, and ranked 796th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Rigel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rigel Pharmaceuticals is 7.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.67.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rigel Pharmaceuticals is 7.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.76.

  • Price to Book Value per Share Ratio

    Rigel Pharmaceuticals has a P/B Ratio of 8.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Rigel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.39% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 5.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rigel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rigel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.39% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 5.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rigel Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    20 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.48% of the stock of Rigel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rigel Pharmaceuticals' insider trading history.
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RIGL Stock News Headlines

Small Washington, DC Group Could Crash US Stocks
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
This ‘Darling’ Pharma Stock Is Hitting New Highs
Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $38.20
See More Headlines

RIGL Stock Analysis - Frequently Asked Questions

Rigel Pharmaceuticals' stock was trading at $16.82 at the start of the year. Since then, RIGL shares have increased by 137.0% and is now trading at $39.8660.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Tuesday, August, 5th. The biotechnology company reported $3.28 EPS for the quarter, topping analysts' consensus estimates of $1.97 by $1.31. The biotechnology company had revenue of $101.69 million for the quarter, compared to the consensus estimate of $64.58 million. Rigel Pharmaceuticals had a net margin of 36.51% and a trailing twelve-month return on equity of 438.89%.
Read the conference call transcript
.

Rigel Pharmaceuticals's stock reverse split before market open on Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Rigel Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (8.92%), Soleus Capital Management L.P. (3.67%), Acadian Asset Management LLC (3.49%) and Geode Capital Management LLC (2.33%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno and David A Santos.
View institutional ownership trends
.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
8/05/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RIGL
CIK
1034842
Employees
160
Year Founded
1996

Price Target and Rating

High Price Target
$57.00
Low Price Target
$23.00
Potential Upside/Downside
-3.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$5.41
Trailing P/E Ratio
7.34
Forward P/E Ratio
180.59
P/E Growth
N/A
Net Income
$17.49 million
Net Margins
36.51%
Pretax Margin
37.00%
Return on Equity
438.89%
Return on Assets
57.03%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
2.02
Quick Ratio
1.90

Sales & Book Value

Annual Sales
$179.28 million
Price / Sales
3.98
Cash Flow
$1.03 per share
Price / Cash Flow
38.58
Book Value
$4.57 per share
Price / Book
8.69

Miscellaneous

Outstanding Shares
17,940,000
Free Float
16,237,000
Market Cap
$712.76 million
Optionable
Optionable
Beta
1.21

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:RIGL) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners